Literature DB >> 36199701

In-Cell Western Protocol for Semi-High-Throughput Screening of Single Clones.

Arpita S Pal1,2, Alejandra M Agredo1,2, Andrea L Kasinski1.   

Abstract

The in-cell western (ICW) is an immunocytochemical technique that has been used to screen for effects of siRNAs, drugs, and small molecule inhibitors. The reduced time and number of cells required to follow this protocol illustrates its semi-high-throughput nature. Performing a successful ICW protocol requires fixing and permeabilizing adherent cells directly in the plate that specifically exposes the epitope of interest. After blocking of non-specific proteins, the cells are incubated overnight with a primary antibody of interest, which is detected via a host-specific near-infrared fluorescently labeled LI-COR secondary antibody. In the final step, the plate is scanned using an Odyssey LI-COR Imaging System or similar, and each of the wells is quantified. For the first time, this technique has been demonstrated to be reproducibly utilized for semi-high-throughput selection of knockout or overexpression clones. Graphical abstract.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  CRISPR-Cas9 ; Doxycycline ; High-throughput ; In-cell western ; Knockout ; LI-COR ; Overexpression ; Screen validation ; Single clone selection

Year:  2022        PMID: 36199701      PMCID: PMC9486692          DOI: 10.21769/BioProtoc.4489

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  9 in total

1.  Validation of high-throughput genotoxicity assay screening using γH2AX in-cell western assay on HepG2 cells.

Authors:  Laure Khoury; Daniel Zalko; Marc Audebert
Journal:  Environ Mol Mutagen       Date:  2013-09-17       Impact factor: 3.216

2.  Quantitative Analysis of Signal Transduction with In-Cell Western Immunofluorescence Assays.

Authors:  Vince Boveia; Amy Schutz-Geschwender
Journal:  Methods Mol Biol       Date:  2015

Review 3.  InVivo Cancer-Based Functional Genomics.

Authors:  Chennan Li; Andrea L Kasinski
Journal:  Trends Cancer       Date:  2020-08-19

4.  Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.

Authors:  Arpita S Pal; Alejandra Agredo; Nadia A Lanman; Jihye Son; Ikjot Singh Sohal; Manvir Bains; Chennan Li; Jenna Clingerman; Kayla Gates; Andrea L Kasinski
Journal:  Cancer Res       Date:  2022-04-15       Impact factor: 13.312

5.  A high-throughput, cell-based screening method for siRNA and small molecule inhibitors of mTORC1 signaling using the In Cell Western technique.

Authors:  Gregory R Hoffman; Nathan J Moerke; Max Hsia; Caroline E Shamu; John Blenis
Journal:  Assay Drug Dev Technol       Date:  2010-04       Impact factor: 1.738

6.  Screening for MAPK modulators using an in-cell western assay.

Authors:  Simon Schnaiter; Beatrix Fürst; Johannes Neu; Frigyes Wáczek; László Orfi; György Kéri; Lukas A Huber; Winfried Wunderlich
Journal:  Methods Mol Biol       Date:  2014

Review 7.  RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes.

Authors:  Sean E Humphrey; Andrea L Kasinski
Journal:  J Hematol Oncol       Date:  2015-04-02       Impact factor: 17.388

8.  CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response.

Authors:  Karol Szlachta; Cem Kuscu; Turan Tufan; Sara J Adair; Stephen Shang; Alex D Michaels; Matthew G Mullen; Natasha Lopes Fischer; Jiekun Yang; Limin Liu; Prasad Trivedi; Edward B Stelow; P Todd Stukenberg; J Thomas Parsons; Todd W Bauer; Mazhar Adli
Journal:  Nat Commun       Date:  2018-10-15       Impact factor: 14.919

9.  A genome scale overexpression screen to reveal drug activity in human cells.

Authors:  Anthony Arnoldo; Saranya Kittanakom; Lawrence E Heisler; Anthony B Mak; Andrey I Shukalyuk; Dax Torti; Jason Moffat; Guri Giaever; Corey Nislow
Journal:  Genome Med       Date:  2014-04-29       Impact factor: 11.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.